Developing Economic Data to Support Private Payer and CMS Reimbursement
Wednesday, March 10, 2010
Webinar | 2:00 - 3:30pm EST
The adoption of new medical technologies and the relative utilization of existing modalities are increasingly driven by economic arguments, a trend destined to continue under health care reform. The strength and credibility of your economic evidence can dramatically affect your primary and secondary markets. CMS demonstration projects reward cost-efficient providers and technologies. Many commercial health plans have formally integrated cost-effectiveness into tech assessment programs. Hospitals rely on Value Analysis Committees for cost-benefit analyses of new and existing technologies.
Incorporating the collection of economic data into your overall evidence-development plan is an important and effective strategy. The case for technology adoption is far stronger when supported by evidence of, e.g., reduced direct costs to hospitals and other providers, earlier treatments resulting in reduced length and cost of episodes of care, fewer adverse events, enhanced efficiency, lower subsequence recurrences and readmissions, fewer requirements for ancillary services, or a shift of care to less restrictive settings.
Who Should Attend
Medical technology professionals in the areas of: reimbursement, quality measures and outcomes, clinical evidence development, product development, market research, and business development.Registration
| AdvaMed Member | $295 | Register Now |
| Non-Member | $395 |
Agenda Overview
In this webinar, you will learn how to:
- Effectively incorporate economics into your clinical studies and/or registries from IRB approval and site agreements to generate publishable results and useful economic models;
- Access Medicare and commercial payer claim data sets that can supplement your clinical study results with economic baselines for existing standards of care or for technologies with a prior adoption history;
- Use databases for retrospective economic analyses after the conclusion of a formal clinical study;
- Express your results in a form most appropriate and useful for private payers (e.g. per member per month).
Speakers
Paul Kane, Vice President, Underwriting Services, IBCDavid Gregory, Executive Vice President, Presscott Associates, Ltd.
General Information
It is the responsibility of the registrant to verify their company’s active membership status prior to registering. You may check if your company is an active member by clicking here. There will be no adjustments or refunds made for registrations made as non-members, when registrant’s company is a member company. Higher non-member rate will be charged for registrations received under member registration when companies are found to be non-members.For Sponsorship Opportunities and Seminar Logistics, please contact Veronica Allen. For information regarding Registration issues, please contact Katia Kunze.
CANCELLATION & REFUND POLICY
All cancellations must be received in writing by Katia Kunze. All cancellations received 11 business days or more prior to the start of the program are subject to a ten percent cancellation fee. There will be NO REFUNDS for cancellations received within the 10 business days prior to the start of the program including "no shows".
We welcome substitutions in lieu of cancellations at any time. Please contact Katia Kunze with the substitute's information. All cancellation refunds will be processed within 30 business days from date cancellation request is received.
Topics and speakers are subject ot change without notice. Advamed reserves the right to cancel or reschedule any program, whereupon full registration feew will be refunded or applied to the rescheduled program in accordance with the registrant's preference. In the event of cancelled programs, AdvaMed assumes no responsibility for transportation, hotel, or other expenses incurred by registrants.